Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

S. Finn, Richard; Ryoo, Baek-Yeol; Merle, Philippe; Kudo, Masatoshi; Bouattour, Mohamed; Yeong Lim, Ho; Breder, Valeriy; Edeline, Julien; Chao, Yee; Ogasawara, Sadahisa; Yau, Thomas; Garrido, Marcelo; L. Chan, Stephen; Knox, Jennifer; Daniele, Bruno; W. Ebbinghaus, Scot; Chen, Erluo; B. Siegel, Abby; X. Zhu, Andrew; Cheng, Ann-Lii; behalf of the KEYNOTE-240 investigators, on

doi:10.1200/jco.19.01307

Public

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.

Shared by NobleBlocks on Dec 2, 2019 • 12:00 AM UTC

Authors:

R. Finn

B. Ryoo

P. Merle

Abstract

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab in this population. PATIENTS AND METHODS This randomized, dou...

Subject

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!